Pliant Therapeutics Presents Data at The Digital International Liver Congress™ 2020
"Our research, to date, has generated encouraging evidence supporting the rationale for directly targeting the TGF-β activation pathway via integrin inhibition in fibrotic diseases," said Éric Lefebvre, M.D., chief medical officer of Pliant Therapeutics. "We believe this novel approach could potentially provide meaningful antifibrotic benefits in patients with chronic liver diseases including PSC and NASH."
Details for both the oral presentation and poster at The Digital ILC 2020 are as follows:
Oral Presentation Title: PLN-74809, a clinical stage, dual αvβ6 αvβ1 integrin inhibitor, reduces fibrosis in a preclinical model of biliary fibrosis and precision cut liver slices from primary sclerosing cholangitis and primary biliary cholangitis patients (AS-144)
Date & Time:
Session: Liver Fibrosis
Poster Title: Reduction in types I and III collagen gene expression by an αvβ1 integrin inhibitor correlates with a decrease in PRO-C1 and PRO-C3 levels in precision-cut liver tissue slices
from cirrhotic nonalcoholic steatohepatitis patients (FRI-237)
Date & Time:
Session: Fibrosis
Both presentations will be available to registered participants via the ILC 2020 website.
About
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, which include those regarding our research and potential antifibrotic benefits, are subject to risks and uncertainties identified under the heading "Risk Factors" included in our quarterly report on Form 10-Q for the quarter ended
Investor Contact:
ir@pliantrx.com
Media Contact:
(619) 849-5390
cambria@canalecomm.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/pliant-therapeutics-presents-data-at-the-digital-international-liver-congress-2020-301119349.html
SOURCE